- Home
- DC vs CRDF Comparison
DC vs CRDF Comparison
Compare DC & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DC
- CRDF
- Stock Information
- Founded
- DC 2017
- CRDF 1999
- Country
- DC United States
- CRDF United States
- Employees
- DC N/A
- CRDF N/A
- Industry
- DC Precious Metals
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DC Basic Materials
- CRDF Health Care
- Exchange
- DC Nasdaq
- CRDF Nasdaq
- Market Cap
- DC 209.6M
- CRDF 196.2M
- IPO Year
- DC N/A
- CRDF N/A
- Fundamental
- Price
- DC $2.88
- CRDF $2.72
- Analyst Decision
- DC Buy
- CRDF Strong Buy
- Analyst Count
- DC 1
- CRDF 4
- Target Price
- DC $7.50
- CRDF $12.25
- AVG Volume (30 Days)
- DC 488.0K
- CRDF 1.0M
- Earning Date
- DC 05-08-2025
- CRDF 05-08-2025
- Dividend Yield
- DC N/A
- CRDF N/A
- EPS Growth
- DC N/A
- CRDF N/A
- EPS
- DC N/A
- CRDF N/A
- Revenue
- DC N/A
- CRDF $587,000.00
- Revenue This Year
- DC N/A
- CRDF N/A
- Revenue Next Year
- DC N/A
- CRDF N/A
- P/E Ratio
- DC N/A
- CRDF N/A
- Revenue Growth
- DC N/A
- CRDF N/A
- 52 Week Low
- DC $1.84
- CRDF $2.01
- 52 Week High
- DC $3.50
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- DC 55.06
- CRDF 45.60
- Support Level
- DC $2.77
- CRDF $2.42
- Resistance Level
- DC $3.10
- CRDF $2.91
- Average True Range (ATR)
- DC 0.11
- CRDF 0.17
- MACD
- DC 0.02
- CRDF 0.03
- Stochastic Oscillator
- DC 56.25
- CRDF 48.48
About DC Dakota Gold Corp.
Dakota Gold Corp is a gold exploration and development company with a specific focus on revitalizing the Homestake District in Lead, South Dakota. Dakota Gold has high-caliber gold mineral properties covering over 48 thousand acres surrounding the historic Homestake Mine.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.